Randomized controlled trial of acute ketamine versus midazolam for recurrence of suicidality in adolescents (TASK): Rationale, design, and baseline characteristics
Contemporary Clinical Trials · 2026-11 · 170 · 108498
DOI: 10.1016/j.cct.2026.108498 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026-11. Verfasst von Madhukar H Trivedi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern …. Hauptthemen laut MEDLINE: Ketamine, Midazolam, Suicide Prevention. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Institute of Mental Health.
Abstract (Originalsprache)
Suicide is one of the leading causes of death among adolescents in the United States. The 'Acute Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents' (TASK), a double-blind, randomized, controlled trial, was designed to examine the signal for efficacy of ketamine, compared to midazolam (active control), in reducing 1) repeat suicidal events, 2) implicit cognition, and 3) depression symptoms and suicidal thoughts and behaviors in adolescents (ages 13-18 years) with recent suicidal events. The report describes the study rationale and design, and the baseline cohort characteristics. Participants were randomized (1:1) to receive either intravenous ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) for four infusions during the first two weeks (days 0, 3, 7, 10). Participants completed follow-up assessment visits weekly through week 12 (twice weekly during the first two weeks) to monitor outcomes. Of the 70 participants who consented/assented to screening, 55 were deemed eligible, and 50 were randomized to ketamine or midazolam. The participants were 82% female and 64% White, with a mean age of 15.4 years (SD = 1.6). On average, the adolescents had three lifetime suicide attempts (SD = 2), two inpatient hospitalizations for lifetime suicidal ideation (SD = 2), and one lifetime emergency evaluation for suicidal ideation (SD = 1). Approximately three out of four youth (74%) reported moderate to severe depression, and 54% reported moderate to severe anxiety. TASK study findings may inform the use of ketamine to reduce suicidal events in youths with recent suicidal events. Clinical Trial Registration: The trial is registered with ClinicalTrials.gov (NCT04592809; date of registration - 10.19.2020).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America. Electronic…
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America.
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America; Children's…
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America; The Abigai…
- Children's Health, Children's Medical Center, Dallas, TX, United States of America; Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of A…
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America; Peter O'Do…
Förderung
- National Institute of Mental Health
Zitieren
APA
Trivedi, M. H., Chin Fatt, C. R., Ayvaci, E. R., Mayes, T. L., Jha, M. K., Pak, T. K., Rebstock, S., Spain, T., Walsh, D., Kimatian, S., Monastirsky, M., Vasu, S., Carmody, T. J., Minhajuddin, A., Kennard, B. D., & Emslie, G. J. (2026). Randomized controlled trial of acute ketamine versus midazolam for recurrence of suicidality in adolescents (TASK): Rationale, design, and baseline characteristics. Contemporary Clinical Trials, 170, 108498. https://doi.org/10.1016/j.cct.2026.108498
Vancouver
Trivedi MH, Chin Fatt CR, Ayvaci ER, Mayes TL, Jha MK, Pak TK, et al. Randomized controlled trial of acute ketamine versus midazolam for recurrence of suicidality in adolescents (TASK): Rationale, design, and baseline characteristics. Contemporary Clinical Trials. 2026;170:108498. doi:10.1016/j.cct.2026.108498
BibTeX
@article{Trivedi2026,
author = {Trivedi, Madhukar H and Chin Fatt, Cherise R and Ayvaci, Emine Rabia and Mayes, Taryn L and Jha, Manish K and Pak, Thomas K and Rebstock, Sarah and Spain, Thomas and Walsh, Deryk and Kimatian, Stephen and Monastirsky, Maria and Vasu, Srividya and Carmody, Thomas J and Minhajuddin, Abu and Kennard, Betsy D and Emslie, Graham J},
title = {Randomized controlled trial of acute ketamine versus midazolam for recurrence of suicidality in adolescents (TASK): Rationale, design, and baseline characteristics},
journal = {Contemporary Clinical Trials},
year = {2026},
volume = {170},
pages = {108498},
doi = {10.1016/j.cct.2026.108498}
}
EUVIMED